We've covered the modest activity of a few mTOR inhibitors in NSCLC (see prior post), so now we'll turn to SCLC.

I go to many meetings in which cases are presented and medical oncologists provide their repsonses about how they'd be inclined to treat a patient. Although we bemoan the lack of much progress in managing small cell lung cancer, one of the effects of that is that there is pretty strong uniformity in how we manage it, since the standards are quite well established.